skip to main content
Idioma:

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

Simões, Eric A.F., MB, BS, DCH, MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda, MS ; Groothuis, Jessie R., MD

Journal of allergy and clinical immunology, 2010-08, Vol.126 (2), p.256-262 [Periódico revisado por pares]

United States: Mosby, Inc

Texto completo disponível

Citações Citado por
  • Título:
    The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children
  • Autor: Simões, Eric A.F., MB, BS, DCH, MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda, MS ; Groothuis, Jessie R., MD
  • Assuntos: Age Factors ; Allergies ; Allergy and Immunology ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Asthma ; Asthma - etiology ; Asthma - prevention & control ; Child, Preschool ; Children & youth ; Disease Susceptibility ; Family medical history ; Female ; Follow-Up Studies ; Food allergies ; Food Hypersensitivity - etiology ; Food Hypersensitivity - prevention & control ; Humans ; Infant ; Infant, Newborn ; lower respiratory tract infection ; Male ; Medicin och hälsovetenskap ; Palivizumab ; Prospective Studies ; recurrent wheezing ; Respiratory Sounds - drug effects ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - complications ; Respiratory Syncytial Virus Infections - drug therapy ; Respiratory Syncytial Viruses ; Respiratory Tract Infections - complications ; Respiratory Tract Infections - drug therapy ; Risk Factors
  • É parte de: Journal of allergy and clinical immunology, 2010-08, Vol.126 (2), p.256-262
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-1
    content type line 23
    The Palivizumab Long Term Respiratory Outcomes Study Group: Germany: Dr V. Stephan, Department of Pediatrics, St Josef Hospital, Ruhr University, Bochum. Dr G. Munch, Dr von Haunersches Kinderspital, Munchen. Dr R. Berner, University Children's Clinic, Freiburg. Spain: IRIS Study group. Coordinator: X. Carbonell-Estrany, Hospital Clínic, Barcelona. Dr J. Figueras, Hospital Clinic, Barcelona. Dr C. Pedraz, Hospital Clínico, Salamanca. Dr A. Remesal Escalero, Hospital Clínico, Salamanca. Dr J. Fraga, Complejo Hospitalario Universitario de Santiago de Compostela. Dr M. I. Martinez Soto, Complejo Hospitalario Universitario de Santiago de Compostela. Dr J. Perez Frias, Hospital Materno-Infantil Carlos Haya, Málaga. Dr J. Blasco Alonso, Hospital Materno-Infantil Carlos Haya, Málaga. Dr E. Narbona, Hospital Clínico San Cecilio, Granada. Dr J. Maldonado Lozano, Hospital Clínico San Cecilio, Granada. Dr V. Roques, Hospital La Fe, Valencia. Dr M. Roques Escolar Hospital La Fe, Valencia. Dr S. Salas Hernandez, Hospital La Paz, Madrid. Dr M. Tabeada Perianes, Hospital Juan Canalejo, Coruna. Dr J. L. Fernández Trisac, Hospital Juan Canalejo, Coruna. I. Echaniz, Hospital de Basurto, Bilbao. Dr A. Aguirre Conde, Hospital de Basurto, Bilbao. Dr S. Salcedo Abizanda, Hospital Valle de Hebron, Barcelona. Dr J. Vinzo Gil Hospital Valle de Hebron, Barcelona. Dr J. Ortiz Tardio, Hospital Gral Jerez de la Frontera, Cádiz. Dr A. Perez Sanchez, Hospital Virgen del Rocío, Sevilla. Dr M. C. Macias Díaz, Hospital Virgen del Rocío, Sevilla. Dr J. López Sastre, Hospital Central de Asturias, Oviedo. Dr B. Fernández Colomer, Hospital Central de Asturias, Oviedo. Dr J. Guzman Cabañas, Hospital Reina Sofía, Córdoba. Dr L. Garcia, Hospital Severo Ochoa, Leganes-Madrid. Dr B. Jimenez Cobo, Hospital General de Alicante, Alicante. Dr R. García Martínez, Hospital General de Alicante, Alicante. Canada: Dr K. Sankaran, Royal University Hospital, Saskatoon. Dr A. Singh, Children and Women's Health Centre, Vancouver. Dr I. Mitchell, Alberta's Children Hospital, Calgary. Sweden: Prof H. Lagercrantz, Department of Neonatal Unit, Astrid Lindgren Children's Hospital, Stockholm. Dr I. Tessin, Department of Neonatalogy Drottning Silvias Barnsjukhus, Gotenborg. Poland: Prof J. Gadzinowski, Katedra I Clinic Neonatal, Poznan. Prof J. Pietrzyk, Katedra Pediatric Amerykanskiego Institute, Krakow. The Netherlands: Prof J. L. L. Kimpen, Wilhelmina Children's Hospital, Utrecht. Abbott International: Dr Jessie Groothuis, Dr P. Pollack, M. McCue, S. Williamsom, M. S. King, D. Morris. Colorado: Dr E. A. F. Simoes, The Children's Hospital, University of Colorado School of Medicine, Denver.
  • Descrição: Background Although respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) in early life are followed by later airway hyperreactivity, it is unclear whether there is a causal relationship between this and an atopic diathesis. Objectives To separate the effects of RSV LRTI and an atopic diathesis on subsequent recurrent wheezing, we examined the protective effect of previous palivizumab administration against subsequent recurrent wheeze in infants with and without a family history of atopy. Methods A prospective multicenter, matched, double cohort study was conducted in 27 centers in Europe and Canada. The rates of physician-diagnosed recurrent wheezing in premature infants <36 weeks gestation who had received palivizumab in the first year of life were compared to those of gestational age–matched controls. Results The relative protective effect of palivizumab on physician-diagnosed recurrent wheezing through the ages of 2 to 5 years was 68% in those with no family history of asthma (odds ratio, 0.32; (95% CI, 0.14-0.75; N = 146 palivizumab-treated, 171 untreated) and 80% in those with no family history of atopy or food allergies (odds ratio, 0.20; 95% CI, 0.07-0.59; N = 101 palivizumab-treated, 100 untreated). In contrast, there was no effect of palivizumab on subsequent recurrent wheezing in the 90 children with a family history of atopy or food allergies compared to 130 untreated infants with atopic families. Conclusion Respiratory syncytial virus prophylaxis in nonatopic children decreases by 80% the relative risk of recurrent wheezing but does not have any effect in infants with an atopic family history. This suggests that RSV predisposes to recurrent wheezing in an atopy-independent mechanism.
  • Editor: United States: Mosby, Inc
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.